• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    UK Companion Diagnostics Oncology Market

    ID: MRFR/MED/48450-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    UK Companion Diagnostics Oncology Market Research Report By Technology (Next Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, Immunohistochemistry), By Applications (Therapeutic Monitoring, Patient Stratification, Predictive Testing, Disease Diagnosis), By End-user (Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies), and By Test Type (Genetic Tests, Protein Biomarker Tests, MicroRNA Tests, Pathological Analysis)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    UK Companion Diagnostics Oncology Market Research Report- Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    UK Companion Diagnostics Oncology Market Summary

    The United Kingdom UK Companion Diagnostics Oncology market is projected to grow significantly from 256.9 million USD in 2024 to 580 million USD by 2035.

    Key Market Trends & Highlights

    UK Companion Diagnostics Oncology Key Trends and Highlights

    • The market is expected to achieve a compound annual growth rate (CAGR) of 7.68% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 580 million USD, indicating robust growth potential.
    • In 2024, the market is valued at 256.9 million USD, reflecting a strong foundation for future expansion.
    • Growing adoption of personalized medicine due to increasing demand for targeted therapies is a major market driver.

    Market Size & Forecast

    2024 Market Size 256.9 (USD Million)
    2035 Market Size 580 (USD Million)
    CAGR (2025-2035) 7.68%

    Major Players

    Illumina, Hologic, Bristol-Myers Squibb, BioRad Laboratories, Merck, Genomic Health, Asuragen, Myriad Genetics, Dako, Thermo Fisher Scientific, Agilent Technologies, Pfizer, AbbVie, Roche, Qiagen

    UK Companion Diagnostics Oncology Market Trends

    The rising incidence of cancer and the need for individualized treatment are the main factors propelling the UK companion diagnostics oncology market's notable expansion. Adopting targeted medicines, which necessitate strong companion diagnostics to guarantee optimal therapy, has been spearheaded by the National Health Service (NHS).

    Furthermore, improvements in biomarker identification and genetic testing are becoming important market drivers since they enable more accurate treatment plans and improved patient outcomes. With UK regulatory bodies expediting clearance procedures, recent trends show that the regulatory environment is shifting in favor of companion diagnostics breakthroughs.

    Faster access to new diagnostic tools is making it possible for medical professionals to more effectively incorporate these solutions into clinical practice. An atmosphere that is conducive to innovation and advancement in the companion diagnostics field is also being created by the increasing cooperation between biotech companies, pharmaceutical corporations, and academic institutions.

    Enhancing healthcare personnel's knowledge and education about the advantages of companion diagnostics in oncology is one opportunity that needs to be investigated. Additionally, there is a chance to increase patient access to diagnostic testing by utilising digital health technologies like telemedicine and health informatics.

    All things considered, the UK market is expected to grow further due to a mix of legislative support, technological improvement, and a determined attempt to enhance cancer treatment through individualized methods.

    UK Companion Diagnostics Oncology Market Drivers

    Market Segment Insights

    Companion Diagnostics Oncology Market Technology Insights

    The UK Companion Diagnostics Oncology Market is significantly influenced by advancements in technology, making it a critical area for growth and innovation. Technology within this market encompasses various methodologies, including Next Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry.

    Next Generation Sequencing holds considerable importance as it enhances personalized medicine by enabling comprehensive genomic profiling, which assists in understanding patient-specific tumor profiles and tailoring targeted therapies accordingly. Polymerase Chain Reaction is widely recognized for its role in detecting genetic mutations and biomarkers associated with various cancer types, proving essential for guiding treatment decisions.

    In Situ Hybridization contributes to the diagnostic landscape by allowing for the visualization of specific nucleic acid sequences within tissue samples, thus helping in the identification of cancerous tissues and determining the prognosis. Immunohistochemistry is also vital as it enables the detection of specific proteins in cancerous tissues, aiding pathologists in assessing tumor characteristics and therapeutic targets.

    Collectively, these technologies serve as foundational components in the UK Companion Diagnostics Oncology Market, supporting the development of effective treatment strategies, fostering improved patient outcomes, and addressing the growing need for precision in oncology. The continued integration of such technologies is expected to further enhance the capabilities in cancer detection and management, addressing both challenges and opportunities within the healthcare system.

    As the NHS and the wider UK healthcare community navigate evolving cancer treatment paradigms, these technologies will play a pivotal role in aligning with the country's focus on personalized medicine and improved patient care pathways.

    Companion Diagnostics Oncology Market Applications Insights

    The Applications segment of the UK Companion Diagnostics Oncology Market is a critical component driving advancements in personalized medicine, which is gaining traction in the healthcare system. With a growing emphasis on patient-centric approaches, Therapeutic Monitoring plays a vital role by facilitating real-time adjustments to treatment plans based on individual responses, thereby optimizing therapeutic outcomes.

    Patient Stratification is also significant as it helps identify the most suitable candidates for specific therapies, increasing treatment efficacy while reducing unnecessary exposure to ineffective treatments. Predictive Testing is essential for assessing potential responses to therapies, allowing healthcare professionals to make informed decisions that are tailored to each patient's unique genetic profile.

    Lastly, Disease Diagnosis within this segment is pivotal in early intervention strategies, significantly enhancing survival rates by ensuring timely and accurate identification of cancer types. The increasing collaboration between government agencies and industry stakeholders in the UK further supports the growth and innovation within these applications, fostering an environment where advanced diagnostics can substantially impact oncology care. As the market evolves, these applications are expected to contribute significantly to establishing a more effective and efficient oncology landscape in the UK.

    Companion Diagnostics Oncology Market End-user Insights

    The End-user segment of the UK Companion Diagnostics Oncology Market plays a crucial role in advancing personalized medicine. Hospitals are the primary providers of care and testing, facilitating the integration of companion diagnostics into treatment plans, which enhances patient outcomes through tailored therapies.

    Diagnostic Laboratories are vital for offering precise testing services, enabling the accurate identification of biomarkers that inform treatment decisions. Research Institutions contribute significantly to the development and validation of new diagnostic tests, enhancing innovation within the field by fostering collaboration with pharmaceutical companies.

    Pharmaceutical Companies are integral in driving the adoption of companion diagnostics as they increasingly align drug development with diagnostic technologies to improve therapeutic efficacy. This segment's growth is fueled by an increasing prevalence of cancer and an emphasis on targeted therapies, creating numerous opportunities for expansion.

    The UK has a supportive regulatory framework that encourages collaborations, enhancing the potential for advancements in companion diagnostics, ultimately benefiting patient management in oncology.

    Companion Diagnostics Oncology Market Test Type Insights

    The UK Companion Diagnostics Oncology Market encompasses various test types that play a critical role in tailoring cancer treatment to individual patients, thereby enhancing the efficacy of therapeutic strategies. Among these, Genetic Tests are pivotal as they help identify hereditary mutations that could influence treatment decisions and patient outcomes.

    Protein Biomarker Tests are gaining prominence for their ability to measure specific protein expression levels, providing insights into tumor characteristics and behavior. MicroRNA Tests are emerging as a vital tool for understanding the regulatory mechanisms in cancer biology, offering the potential for new therapeutic targets.

    Pathological Analysis remains a cornerstone of oncology diagnostics, serving as the cornerstone for diagnosing cancer and determining the appropriate course of treatment. As the healthcare landscape in the UK increasingly embraces personalized medicine, these test types are expected to drive both innovation and market expansion within the UK Companion Diagnostics Oncology Market.

    The increasing focus on precision oncology is fueled by advancements in technology and an increasing demand for effective cancer therapies, creating opportunities for growth in these testing methodologies.

    Get more detailed insights about UK Companion Diagnostics Oncology Market Research Report- Forecast to 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The UK Companion Diagnostics Oncology Market is an integral component of the broader healthcare landscape, reflecting the growing emphasis on personalized medicine in oncology. Companion diagnostics are critical in enabling precise patient stratification and treatment selection, thereby enhancing the efficacy of targeted therapies.

    In this competitive arena, various players are striving to innovate and deliver advanced diagnostic solutions that facilitate informed clinical decisions. The landscape is characterized by a combination of established companies and emerging entities that are continually adapting to the evolving needs of the healthcare sector.

    As the demand for personalized cancer treatment increases, so does the importance of effective partnerships, technological advancements, and regulatory compliance, all of which play crucial roles in shaping the market dynamics.

    Illumina stands out in the UK Companion Diagnostics Oncology Market with its robust portfolio of next-generation sequencing (NGS) solutions that significantly enhance the speed and accuracy of cancer diagnostics. The company's strengths lie in its advanced technology and its ability to develop comprehensive genomic profiling services that aid in the identification of biomarkers crucial for personalized treatment plans.

    Illumina's presence in the UK is marked by collaborations with various healthcare institutions and research organizations, ensuring a continuous flow of innovative solutions tailored to the local market. The firm's commitment to research and development keeps it at the forefront of advancements in genomic medicine, solidifying its position as a key player in the UK oncology landscape.

    Hologic also holds a significant position in the UK Companion Diagnostics Oncology Market, primarily focusing on women's health and oncology. The company's key products and services include advanced molecular diagnostic solutions designed for the detection of various cancers, particularly those related to women's health.

    Hologic's strengths encompass a strong emphasis on research and development, leading to a suite of innovative diagnostic tests that facilitate timely and accurate clinical decisions. The company maintains a robust market presence through strategic partnerships and collaborations aimed at expanding its product offerings in the UK.

    Its efforts are complemented by a series of mergers and acquisitions that have enriched its capabilities and broadened its market reach, enabling Hologic to provide comprehensive diagnostic solutions that address the specific needs of the UK oncology market.

    Key Companies in the UK Companion Diagnostics Oncology Market market include

    Industry Developments

    The UK Companion Diagnostics Oncology Market has seen notable developments recently, especially with companies like Illumina and Merck making strides in precision medicine. In September 2023, Illumina announced partnerships aimed at enhancing their genomic profiling capabilities, contributing to a significant boost in their market valuation.

    Bristol-Myers Squibb also emphasized integrating companion diagnostics into their treatment pathways, reflecting a trend toward tailored therapies. Acquisitions have been prominent, with BioRad Laboratories acquiring a smaller diagnostics firm in August 2023, a move that is expected to fortify their portfolio in oncology diagnostics.

    On the other hand, Thermo Fisher Scientific launched a new assay in July 2023, enhancing capabilities for detecting genetic mutations associated with various cancers. The UK government continues to support the landscape through initiatives aimed at fostering innovation in biotechnology, allowing companies like Agilent Technologies and Roche to thrive in this environment.

    The market is witnessing a growth trajectory, driven by increasing investments and advancements in technology, positioning the UK as a competitive player in the field of oncology companion diagnostics, reflecting a broader trend in personalized medicine.

    Market Segmentation

    Companion Diagnostics Oncology Market End-user Outlook

    • Hospitals
    • Diagnostic Laboratories
    • Research Institutions
    • Pharmaceutical Companies

    Companion Diagnostics Oncology Market Test Type Outlook

    • Genetic Tests
    • Protein Biomarker Tests
    • MicroRNA Tests
    • Pathological Analysis

    Companion Diagnostics Oncology Market Technology Outlook

    • Next Generation Sequencing
    • Polymerase Chain Reaction
    • In Situ Hybridization
    • Immunohistochemistry

    Companion Diagnostics Oncology Market Applications Outlook

    • Therapeutic Monitoring
    • Patient Stratification
    • Predictive Testing
    • Disease Diagnosis

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 239.4(USD Million)
    MARKET SIZE 2024 256.95(USD Million)
    MARKET SIZE 2035 580.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 7.682% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Illumina, Hologic, Bristol Myers Squibb, BioRad Laboratories, Merck, Genomic Health, Asuragen, Myriad Genetics, Dako, Thermo Fisher Scientific, Agilent Technologies, Pfizer, AbbVie, Roche, Qiagen
    SEGMENTS COVERED Technology, Applications, End User, Test Type
    KEY MARKET OPPORTUNITIES Personalized treatment solutions, Growth in targeted therapies, Increased investment in R&D, Rising prevalence of cancer, Regulatory support for diagnostics
    KEY MARKET DYNAMICS rising cancer prevalence, technological advancements, regulatory approvals, personalized medicine adoption, increasing healthcare expenditure
    COUNTRIES COVERED UK

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the expected market size of the UK Companion Diagnostics Oncology Market in 2024?

    The UK Companion Diagnostics Oncology Market is expected to be valued at 256.95 million USD in 2024.

    What is the projected market size for the UK Companion Diagnostics Oncology Market by 2035?

    By 2035, the market is projected to reach a value of 580.0 million USD.

    What is the expected compound annual growth rate (CAGR) for the UK Companion Diagnostics Oncology Market between 2025 to 2035?

    The expected CAGR for the UK Companion Diagnostics Oncology Market is 7.682% from 2025 to 2035.

    Which technology segment is projected to have the highest market value in 2035?

    The Next Generation Sequencing segment is anticipated to reach a value of 168.0 million USD in 2035.

    What is the market value for the Polymerase Chain Reaction segment in 2024?

    The Polymerase Chain Reaction segment is valued at 65.0 million USD in 2024.

    Who are the key players in the UK Companion Diagnostics Oncology Market?

    Major players include Illumina, Hologic, Bristol Myers Squibb, BioRad Laboratories, and Merck.

    How much is the Immunohistochemistry segment valued at in 2024?

    The Immunohistochemistry segment is valued at 70.0 million USD in 2024.

    What is the anticipated market value for In Situ Hybridization in 2035?

    In Situ Hybridization is projected to reach a market value of 100.0 million USD by 2035.

    What growth opportunities exist within the UK Companion Diagnostics Oncology Market?

    Emerging trends include advancements in personalized medicine and an increasing focus on targeted therapies.

    How do the key market players impact the UK Companion Diagnostics Oncology Market?

    The presence of key competitors enhances innovation, drives market expansion, and influences pricing strategies.

    1. EXECUTIVE
    2. SUMMARY
    3. Market Overview
    4. Key Findings
    5. Market Segmentation
    6. Competitive Landscape
    7. Challenges and Opportunities
    8. Future Outlook
    9. MARKET INTRODUCTION
    10. Definition
    11. Scope of the study
    12. Research Objective
    13. Assumption
    14. Limitations
    15. RESEARCH
    16. METHODOLOGY
    17. Overview
    18. Data
    19. Mining
    20. Secondary Research
    21. Primary
    22. Research
    23. Primary Interviews and Information Gathering
    24. Process
    25. Breakdown of Primary Respondents
    26. Forecasting
    27. Model
    28. Market Size Estimation
    29. Bottom-Up
    30. Approach
    31. Top-Down Approach
    32. Data
    33. Triangulation
    34. Validation
    35. MARKET
    36. DYNAMICS
    37. Overview
    38. Drivers
    39. Restraints
    40. Opportunities
    41. MARKET FACTOR ANALYSIS
    42. Value chain Analysis
    43. Porter's
    44. Five Forces Analysis
    45. Bargaining Power of Suppliers
    46. Bargaining
    47. Power of Buyers
    48. Threat of New Entrants
    49. Threat
    50. of Substitutes
    51. Intensity of Rivalry
    52. COVID-19
    53. Impact Analysis
    54. Market Impact Analysis
    55. Regional
    56. Impact
    57. Opportunity and Threat Analysis
    58. UK
    59. Companion Diagnostics Oncology Market, BY Technology (USD Million)
    60. Next
    61. Generation Sequencing
    62. Polymerase Chain Reaction
    63. In
    64. Situ Hybridization
    65. Immunohistochemistry
    66. UK
    67. Companion Diagnostics Oncology Market, BY Applications (USD Million)
    68. Therapeutic
    69. Monitoring
    70. Patient Stratification
    71. Predictive
    72. Testing
    73. Disease Diagnosis
    74. UK
    75. Companion Diagnostics Oncology Market, BY End User (USD Million)
    76. Hospitals
    77. Diagnostic
    78. Laboratories
    79. Research Institutions
    80. Pharmaceutical
    81. Companies
    82. UK Companion Diagnostics
    83. Oncology Market, BY Test Type (USD Million)
    84. Genetic
    85. Tests
    86. Protein Biomarker Tests
    87. MicroRNA
    88. Tests
    89. Pathological Analysis
    90. Competitive Landscape
    91. Overview
    92. Competitive
    93. Analysis
    94. Market share Analysis
    95. Major
    96. Growth Strategy in the Companion Diagnostics Oncology Market
    97. Competitive
    98. Benchmarking
    99. Leading Players in Terms of Number of Developments
    100. in the Companion Diagnostics Oncology Market
    101. Key developments
    102. and growth strategies
    103. New Product Launch/Service Deployment
    104. Merger
    105. & Acquisitions
    106. Joint Ventures
    107. Major
    108. Players Financial Matrix
    109. Sales and Operating Income
    110. Major
    111. Players R&D Expenditure. 2023
    112. Company
    113. Profiles
    114. Illumina
    115. Financial
    116. Overview
    117. Products Offered
    118. Key
    119. Developments
    120. SWOT Analysis
    121. Key
    122. Strategies
    123. Hologic
    124. Financial
    125. Overview
    126. Products Offered
    127. Key
    128. Developments
    129. SWOT Analysis
    130. Key
    131. Strategies
    132. Bristol Myers Squibb
    133. Financial
    134. Overview
    135. Products Offered
    136. Key
    137. Developments
    138. SWOT Analysis
    139. Key
    140. Strategies
    141. BioRad Laboratories
    142. Financial
    143. Overview
    144. Products Offered
    145. Key
    146. Developments
    147. SWOT Analysis
    148. Key
    149. Strategies
    150. Merck
    151. Financial
    152. Overview
    153. Products Offered
    154. Key
    155. Developments
    156. SWOT Analysis
    157. Key
    158. Strategies
    159. Genomic Health
    160. Financial
    161. Overview
    162. Products Offered
    163. Key
    164. Developments
    165. SWOT Analysis
    166. Key
    167. Strategies
    168. Asuragen
    169. Financial
    170. Overview
    171. Products Offered
    172. Key
    173. Developments
    174. SWOT Analysis
    175. Key
    176. Strategies
    177. Myriad Genetics
    178. Financial
    179. Overview
    180. Products Offered
    181. Key
    182. Developments
    183. SWOT Analysis
    184. Key
    185. Strategies
    186. Dako
    187. Financial
    188. Overview
    189. Products Offered
    190. Key
    191. Developments
    192. SWOT Analysis
    193. Key
    194. Strategies
    195. Thermo Fisher Scientific
    196. Financial
    197. Overview
    198. Products Offered
    199. Key
    200. Developments
    201. SWOT Analysis
    202. Key
    203. Strategies
    204. Agilent Technologies
    205. Financial
    206. Overview
    207. Products Offered
    208. Key
    209. Developments
    210. SWOT Analysis
    211. Key
    212. Strategies
    213. Pfizer
    214. Financial
    215. Overview
    216. Products Offered
    217. Key
    218. Developments
    219. SWOT Analysis
    220. Key
    221. Strategies
    222. AbbVie
    223. Financial
    224. Overview
    225. Products Offered
    226. Key
    227. Developments
    228. SWOT Analysis
    229. Key
    230. Strategies
    231. Roche
    232. Financial
    233. Overview
    234. Products Offered
    235. Key
    236. Developments
    237. SWOT Analysis
    238. Key
    239. Strategies
    240. Qiagen
    241. Financial
    242. Overview
    243. Products Offered
    244. Key
    245. Developments
    246. SWOT Analysis
    247. Key
    248. Strategies
    249. References
    250. Related
    251. Reports
    252. LIST
    253. OF ASSUMPTIONS
    254. UK Companion Diagnostics Oncology Market
    255. SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD Billions)
    256. UK
    257. Companion Diagnostics Oncology Market SIZE ESTIMATES & FORECAST, BY APPLICATIONS,
    258. 2035 (USD Billions)
    259. UK Companion Diagnostics Oncology
    260. Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    261. UK
    262. Companion Diagnostics Oncology Market SIZE ESTIMATES & FORECAST, BY TEST TYPE,
    263. 2035 (USD Billions)
    264. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    265. ACQUISITION/PARTNERSHIP
    266. LIST
    267. Of figures
    268. MARKET SYNOPSIS
    269. UK
    270. COMPANION DIAGNOSTICS ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
    271. UK
    272. COMPANION DIAGNOSTICS ONCOLOGY MARKET ANALYSIS BY APPLICATIONS
    273. UK
    274. COMPANION DIAGNOSTICS ONCOLOGY MARKET ANALYSIS BY END USER
    275. UK
    276. COMPANION DIAGNOSTICS ONCOLOGY MARKET ANALYSIS BY TEST TYPE
    277. KEY
    278. BUYING CRITERIA OF COMPANION DIAGNOSTICS ONCOLOGY MARKET
    279. RESEARCH
    280. PROCESS OF MRFR
    281. DRO ANALYSIS OF COMPANION DIAGNOSTICS
    282. ONCOLOGY MARKET
    283. DRIVERS IMPACT ANALYSIS: COMPANION DIAGNOSTICS
    284. ONCOLOGY MARKET
    285. RESTRAINTS IMPACT ANALYSIS: COMPANION
    286. DIAGNOSTICS ONCOLOGY MARKET
    287. SUPPLY / VALUE CHAIN: COMPANION
    288. DIAGNOSTICS ONCOLOGY MARKET
    289. COMPANION DIAGNOSTICS ONCOLOGY
    290. MARKET, BY TECHNOLOGY, 2025 (% SHARE)
    291. COMPANION DIAGNOSTICS
    292. ONCOLOGY MARKET, BY TECHNOLOGY, 2019 TO 2035 (USD Billions)
    293. COMPANION
    294. DIAGNOSTICS ONCOLOGY MARKET, BY APPLICATIONS, 2025 (% SHARE)
    295. COMPANION
    296. DIAGNOSTICS ONCOLOGY MARKET, BY APPLICATIONS, 2019 TO 2035 (USD Billions)
    297. COMPANION
    298. DIAGNOSTICS ONCOLOGY MARKET, BY END USER, 2025 (% SHARE)
    299. COMPANION
    300. DIAGNOSTICS ONCOLOGY MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    301. COMPANION
    302. DIAGNOSTICS ONCOLOGY MARKET, BY TEST TYPE, 2025 (% SHARE)
    303. COMPANION
    304. DIAGNOSTICS ONCOLOGY MARKET, BY TEST TYPE, 2019 TO 2035 (USD Billions)
    305. BENCHMARKING
    306. OF MAJOR COMPETITORS

    UK Companion Diagnostics Oncology Market Segmentation

     

     

     

    • Companion Diagnostics Oncology Market By Technology (USD Million, 2019-2035)

      • Next Generation Sequencing
      • Polymerase Chain Reaction
      • In Situ Hybridization
      • Immunohistochemistry

     

    • Companion Diagnostics Oncology Market By Applications (USD Million, 2019-2035)

      • Therapeutic Monitoring
      • Patient Stratification
      • Predictive Testing
      • Disease Diagnosis

     

    • Companion Diagnostics Oncology Market By End User (USD Million, 2019-2035)

      • Hospitals
      • Diagnostic Laboratories
      • Research Institutions
      • Pharmaceutical Companies

     

    • Companion Diagnostics Oncology Market By Test Type (USD Million, 2019-2035)

      • Genetic Tests
      • Protein Biomarker Tests
      • MicroRNA Tests
      • Pathological Analysis

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027